BD (NYSE: BDX) announced today that it will spin off its Diabetes Care business as an independent, publicly traded company during the first half of 2022.
The Diabetes Care business saw $1.1 billion in sales during BD’s fiscal year ended Sept. 30, 2020, nearly half outside the U.S. The business manufactures roughly 8 billion injection devices annually, serving about 30 million patients. The new company will have manufacturing sites in the United States, Ireland and China and expected office locations in New Jersey and Massachusetts.
Get the full story on our sister site Drug Delivery Business News.
